TRANSCRIPTION FACTOR BOB1 IS ESSENTIAL FOR GERMINAL CENTER-DERIVED B CELL MALIGNANCIES OFFERING AN ATTRACTIVE TARGET FOR TCR-BASED THERAPY
Author(s): ,
Rogier Reijmers
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Miranda Meeuwsen
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Christiaan Kweekel
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Michelle Kop
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Angelo Meringa
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Lorenz Jahn
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
,
Frederik Falkenburg
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
Mirjam Heemskerk
Affiliations:
Hematology,Leiden University Medical Center,Leiden,Netherlands
EHA Library. Reijmers R. 06/15/19; 266823; PS1206
Rogier Reijmers
Rogier Reijmers
Contributions
Abstract

Abstract: PS1206

Type: Poster Pitch

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Antigen-loss tumor escape variants are a major concern when targeting cancer, while tumor-specific targeting is crucial to prevent unwanted toxicity. Thus, targeting essential cancer- or lineage-specific genes might represent attractive targets for antineoplastic therapies since antigen-loss is less likely to occur, and toxicity is limited. Here, we describe B cell lineage-specific transcriptional coactivator BOB1 to meet these important criteria. Interestingly, in our lab we have successfully identified several distinct T cell receptors (TCRs) that are BOB1-specific with demonstrable preclinical efficacy.

Aims
With this study we aimed to demonstrate that the transcriptional coactivator BOB1 is essential for survival of B cell malignancies with a germinal center origin, and that these neoplasms are recognized by our recently  and newly identified BOB1-specific TCRs in the context of HLA-B*07:02 and HLA-B*35:01, respectively.

Methods
Using a CRISPR/Cas9 puromycin plasmid containing a sgRNA or by applying a doxycycline-inducible system, we set out to target BOB1 in different B cell malignancies. Upon targeting, we selected puromycin resistant single-cell clones or tracked cell growth upon induction, and used sanger-sequencing to identify possible indel mutations. Besides single-cell analysis, Tracking of Indels by DEcomposition (TIDE) was used to accurately quantify the editing efficacy and most prominent types of indel mutation in different pools of B cell tumors. Finally, we performed in vitro co-cultures with BOB1-specific TCR transduced CD8 T cells and a plethora of B cell malignancies, including myeloma and lymphoma, and assessed preclinical efficacy targeting myeloma in vivo.

Results
Remarkably, for each type of B cell tumor used, we were unable to generate BOB1-deficient clones, unveiling the importance for cell survival. In line, using the TIDE algorithm for easy detection of predominant types of indel mutations in targeted pools of distinct types of B cell malignancies, we found unmutated BOB1 sequences only (>90%), while generally a mere 5% is expected to be unaltered for any irrelevant gene. Finally, we further established the essentiality of BOB1 in a broad panel of B cell malignancies containing inducible CRISPR/Cas9, which uniformly resulted in rapid cell death upon induction. Interestingly and importantly, using our recently and newly identified TCRs recognizing peptides derived from BOB1 in the context of HLA-B*07:02 and HLA-B*35:01, we observed highly specific and efficient targeting of a vast majority of B cell malignancies in vitro and in vivo.

Conclusion
Altogether, we postulate BOB1 as an essential B cell lineage-specific target, fortifying gene transfer of our unique TCRs into CD8+ cytotoxic T cells as an efficient therapeutic treatment option for a large variety of B cell neoplasms.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res

Keyword(s): Adoptive immunotherapy, Lymphoma therapy, Myeloma

Abstract: PS1206

Type: Poster Pitch

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Antigen-loss tumor escape variants are a major concern when targeting cancer, while tumor-specific targeting is crucial to prevent unwanted toxicity. Thus, targeting essential cancer- or lineage-specific genes might represent attractive targets for antineoplastic therapies since antigen-loss is less likely to occur, and toxicity is limited. Here, we describe B cell lineage-specific transcriptional coactivator BOB1 to meet these important criteria. Interestingly, in our lab we have successfully identified several distinct T cell receptors (TCRs) that are BOB1-specific with demonstrable preclinical efficacy.

Aims
With this study we aimed to demonstrate that the transcriptional coactivator BOB1 is essential for survival of B cell malignancies with a germinal center origin, and that these neoplasms are recognized by our recently  and newly identified BOB1-specific TCRs in the context of HLA-B*07:02 and HLA-B*35:01, respectively.

Methods
Using a CRISPR/Cas9 puromycin plasmid containing a sgRNA or by applying a doxycycline-inducible system, we set out to target BOB1 in different B cell malignancies. Upon targeting, we selected puromycin resistant single-cell clones or tracked cell growth upon induction, and used sanger-sequencing to identify possible indel mutations. Besides single-cell analysis, Tracking of Indels by DEcomposition (TIDE) was used to accurately quantify the editing efficacy and most prominent types of indel mutation in different pools of B cell tumors. Finally, we performed in vitro co-cultures with BOB1-specific TCR transduced CD8 T cells and a plethora of B cell malignancies, including myeloma and lymphoma, and assessed preclinical efficacy targeting myeloma in vivo.

Results
Remarkably, for each type of B cell tumor used, we were unable to generate BOB1-deficient clones, unveiling the importance for cell survival. In line, using the TIDE algorithm for easy detection of predominant types of indel mutations in targeted pools of distinct types of B cell malignancies, we found unmutated BOB1 sequences only (>90%), while generally a mere 5% is expected to be unaltered for any irrelevant gene. Finally, we further established the essentiality of BOB1 in a broad panel of B cell malignancies containing inducible CRISPR/Cas9, which uniformly resulted in rapid cell death upon induction. Interestingly and importantly, using our recently and newly identified TCRs recognizing peptides derived from BOB1 in the context of HLA-B*07:02 and HLA-B*35:01, we observed highly specific and efficient targeting of a vast majority of B cell malignancies in vitro and in vivo.

Conclusion
Altogether, we postulate BOB1 as an essential B cell lineage-specific target, fortifying gene transfer of our unique TCRs into CD8+ cytotoxic T cells as an efficient therapeutic treatment option for a large variety of B cell neoplasms.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res

Keyword(s): Adoptive immunotherapy, Lymphoma therapy, Myeloma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies